Tesofensine (Capsules)

Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor that selectively inhibits the presynaptic reuptake of dopamine, norepinephrine, and serotonin. Originally investigated for neurological conditions, tesofensine demonstrated potent appetite-suppressing effects in clinical research, producing weight loss approximately twice that of currently available pharmaceuticals. This compound operates through distinct mechanisms from traditional appetite suppressants, modulating hypothalamic feeding centers and increasing satiety signaling without significant stimulant effects. Research indicates tesofensine enhances fat oxidation while producing minimal increases in heart rate or cortisol compared to structural analogs. Preclinical and clinical investigations support its utility in metabolic research, obesity modeling, and neurotransmitter dynamics research.

Chemical Structure and Identification

• Compound Name: Tesofensine (NS-2330)
• Per Capsule: 0.25 mg per capsule
• Molecular Formula: C₁₇H₂₃Cl₂NO
• Molecular Weight: 328.28 g/mol
• CAS Number: 195875-84-4

Research Applications

• Appetite Suppression: Hypothalamic satiety signaling and monoamine transporter modulation [1][2]
• Weight Loss Mechanisms: Body composition changes and metabolic rate alterations in preclinical models [3]
• Neurotransmitter Dynamics: Dopamine, serotonin, and norepinephrine reuptake inhibition [2][4]
• Metabolic Flexibility: Fatty acid oxidation enhancement and fuel substrate utilization [3]
• Energy Expenditure: Nocturnal metabolic rate and thermogenesis research [1]
• Obesity Models: Diet-induced obesity reversal and metabolic syndrome pathways [4]

Reference Citations

1. Astrup A, et al. (2008) – Effect of tesofensine on bodyweight loss in obese patients | https://pubmed.ncbi.nlm.nih.gov/
2. Billes SK, Cowley MA (2010) – Tesofensine induces appetite suppression via alpha1 adrenoceptor and dopamine pathways | https://pubmed.ncbi.nlm.nih.gov/23932919/
3. Sjodin A, et al. (2010) – The triple monoamine reuptake inhibitor tesofensine on energy metabolism | https://pubmed.ncbi.nlm.nih.gov/20479765/
4. Senzacqua M, et al. (2021) – Tesofensine silences GABAergic hypothalamic neurons | https://pmc.ncbi.nlm.nih.gov/articles/PMC11042726/

Important Regulatory Notice

These products are for research use only and are not intended for human consumption, therapeutic use, or diagnostic purposes. All compounds described herein have not been approved by the FDA for human use. These products are strictly intended for in vitro laboratory research and analytical purposes when conducted by qualified research professionals in licensed facilities. Users are responsible for ensuring compliance with all applicable laws regarding purchase and use of these materials.